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Recent evidence from randomized controlled trials has pro-
vided compelling evidence to support the use of β blockers in
most patients with heart failure due to systolic dysfunction.
There is little disagreement about the mortality benefit pro-
vided by adding β blockers to standard therapy, which may
include angiotensin-converting enzyme inhibitors, diuretics,
and sometimes digoxin. A few areas are still controversial.
The authors review the available literature encompassing
four of those controversial areas: 1) the comparability
among β blockers; 2) the utility of β blockers among patients
with New York Heart Association class I and class IV heart
failure symptoms; 3) the impact of race on the effectiveness
of β blockers; and 4) the safety and efficacy of β blockers
among patients on concomitant therapy with angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
or spironolactone. (CHF. 2003;9:255–262) ©2003 CHF, Inc.
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Recent trials have provided compelling evidence to
support the use of β blockers in heart failure (HF)
due to systolic dysfunction.1–4 Current, major pub-
lished guidelines support this concept and offer
guidance on how to administer them in appropriate
patients.5–9 Still, there are controversies. 
The majority of patients with HF may derive
long-term benefit from the addition of β blockers to
background therapy, which may include an-
giotensin-converting enzyme (ACE) inhibitors, loop
diuretics, and digoxin. Only one comparative trial
between β blockers in heart failure has been com-
pleted. This trial did not resolve the issue of com-
parability. Little clinical data exists among patients
with New York Heart Association (NYHA) class I
symptoms and some controversy remains over the
appropriateness of routine administration to pa-
tients with NYHA class IV symptoms. Additionally,
retrospective analyses of prior HF trials10 and one
recently completed β-blocker trial11 have raised the
specter of racial differences in the response of HF
patients to pharmacologic therapy. Finally, there
also remains uncertainty about how β blockers may
interact with other medications. Evidence for the ef-
ficacy of β blockers was being gathered at the same
time that spironolactone was being evaluated for its
use in HF in the Randomized Aldactone Evaluation
Study (RALES).12 As a result, none of the β-blocker
trials were conducted with spironolactone as part of
background therapy and only 10% of the RALES
population was on β blockers. The recently released
Valsartan Heart Failure Trial (Val-HeFT) uncov-
ered a possible adverse interaction among patients
on β blockers with concomitant ACE inhibitors and
angiotensin receptor blockers (ARBs).13
In this paper, we will review the literature de-
scribing these controversies, including: 1) the com-
parability among β blockers; 2) the utility of β
blockers among patients with NYHA class I and
class IV symptoms; 3) the impact of race on the effi-
cacy of β blockers; and 4) the safety and efficacy of
β blockers among patients on concomitant therapy
with ACE inhibitors, ARBs, or spironolactone. 
Controversies in the Use of Beta Blockers
in Heart Failure
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Comparability Among β Blockers
Pharmacologic differences among β blockers sug-
gest that perhaps one β blocker may be preferred to
another in regard to efficacy, tolerability, and prac-
ticality. To evaluate the differences among β block-
ers, this section will focus on pharmacologic, theo-
retical, evidenced-based, and practical issues
among β blockers. This section will deal primarily
with bisoprolol, carvedilol, and metoprolol, which
are three of the four β blockers tested in large mor-
tality trials among HF patients and the only ones
with a proven mortality benefit. Bucindolol is the
fourth β blocker tested and has not demonstrated a
mortality benefit in HF. Bucindolol is not available
in this country. It will be discussed briefly in the
section below on comparability of agents and will be
discussed in more detail in the section on racial dif-
ferences in the response to medications.
Pharmacologic Properties and Theoretical Con-
siderations. Metoprolol and bisoprolol are consid-
ered second generation β blockers, meaning that
they are cardioselective and have no ancillary prop-
erties.14 Third generation β blockers may either be
cardioselective or noncardioselective and may have
potentially important ancillary properties.
Carvedilol is a third generation β blocker that is
noncardioselective with α-blocking properties.14
Bucindolol is also noncardioselective, but without
the α-blocking properties of carvedilol. The phar-
macologic profiles are shown in Table I.
Metoprolol and Bisoprolol. As seen in Table I, meto-
prolol and bisoprolol are cardioselective for the β1
receptor. A potential, theoretical advantage of se-
lective β1 blockade may include the safe administra-
tion to patients with asthma since the β2 receptor is
not blocked. Bisoprolol has even greater selectivity
than metoprolol. In patients with low blood pres-
sure, these β blockers may be better tolerated ini-
tially since they do not possess vasodilating proper-
ties. In regard to the pathophysiology of HF, recent
animal data15–17 have suggested that the β1 receptor
is primarily responsible for the development of di-
lated cardiomyopathy. In one study in mice, over-
expression of the β1 receptor five-fold resulted in
development of dilated cardiomyopathy, whereas
overexpression of the β2 receptor 100-fold resulted
in development of cardiomyopathy.16,17 Other ani-
mal data18,19 have suggested that apoptosis is medi-
ated by the β1 receptor and that stimulation of the
β2 receptor may have antiapoptotic effects. Overall,
these data would favor the use of metoprolol or
bisoprolol since, theoretically, antagonism of the β1
receptor is most critical and nonantagonism of the
β2 receptor is beneficial. 
Carvedilol. Carvedilol blocks β1, β2, and α1 receptors
(Table I). Debatably, the most important driving
force in the development and maintenance of sys-
tolic dysfunction is the activation of the sympathetic
nervous system (i.e., elevated norepinephrine con-
centrations). Theoretically, since the heart contains
three different adrenergic receptors (β1, β2, and α1
receptors) that may be activated by norepinephrine,
blocking all three receptors (complete adrenergic
blockade) vs. just one receptor could be more effi-
cacious. Furthermore, carvedilol also decreases sys-
temic and cardiac adrenergic drive and maintains
downregulation of the β receptor.20 These proper-
ties, along with blocking all three receptors, may
provide the best protection against excess adrener-
gic drive that is present in patients with HF.
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Table I. Pharmacologic Properties
PROPERTY BISOPROLOL BUCINDOLOL CARVEDILOL METOPROLOL
β1 Blockade + + + +
β2 Blockade – + + –
α1 Blockade – – + –
Vasodilation – + (Mild) + (Acute) –
Antioxidant – – + (?) –
Lowers cardiac NE – + + –
Lowers systemic NE – ++ + –
– =does not demonstrate this property; +=demonstrates this property; + (?)=demonstrates this property with a
degree of uncertainty; ++= demonstrates this property to a greater extent; NE=norepinephrine
When a β blocker is initially started in HF patients
in whom cardiac function is highly dependent upon
adrenergic drive, there is a slight drop in cardiac out-
put. The α-blocking properties of carvedilol mediate
vasodilatation that may decrease afterload and negate
this drop in cardiac output. This affect may allow for
less chance of decompensation on initiation of thera-
py. For metoprolol and bisoprolol, their mechanism
for maintaining cardiac output would be unopposed
stimulation of β2 receptors in the periphery. 
Carvedilol may also possess antioxidant proper-
ties that could theoretically be beneficial in HF pa-
tients. Antioxidant effects may result in antiprolif-
erative effects, improved endothelial function, de-
creased ischemic-induced damage, and apoptosis.
Any of these effects would be beneficial in HF pa-
tients since each of these effects may contribute to
the maintenance and progression of HF.
Evidence Base. From a theoretical perspective, it can
be argued that each β blocker should be the “best” for
treating HF patients. To determine whether or not
these theoretical arguments actually translate into
clinical benefit, evaluation of the available clinical
data is required. For this purpose, studies evaluating
end points such as mortality, hospitalizations, tolera-
bility, and left ventricular ejection fraction will be dis-
cussed. For mortality, hospitalizations, and tolerabili-
ty, the four largest placebo-controlled trials will be
evaluated: Cardiac Insufficiency Bisoprolol Study II
(CIBIS II),1 Metoprolol Randomized Intervention
Trial in Heart Failure (MERIT-HF),2 Carvedilol
Prospective Randomized Cumulative Survival Study
Group (CORPERNICUS),4 and Beta-Blocker Evalua-
tion of Survival Trial (BEST).11 Additional mention
will be given to the US Carvedilol Heart Failure Tri-
als.3 Finally, the Carvedilol or Metroprolol European
Trial (COMET)21 will be reviewed.
Mortality. There are randomized, placebo-controlled
mortality trials on four different agents that can be
evaluated. As seen in Table II, the risk reduction
among the trials appears to be similar with the excep-
tion of the BEST trial which is the only large mortality
trial in which no mortality benefit was detected.11 The
largest mortality benefit was reported from the US
Carvedilol Heart Failure Trial which demonstrated a
65% reduction in mortality.3 Whether or not the risk
reduction seen in this trial is actually that great is a
matter of debate, since it was not specifically designed
as a mortality trial like the other three trials and data
from four separate trials were combined to achieve
their end point. Furthermore, only one of the four tri-
als demonstrated a mortality benefit. Additionally,
deaths during the single blind run-in were not includ-
ed in the analysis. It should also be noted that, among
the positive trials, the placebo mortality rate was high-
est and left ventricular ejection fraction was lowest for
the COPERNICUS trial, which makes head-to-head
comparisons using these data difficult.4 However, in
post hoc analyses of patients with severe HF in the
MERIT-HF and CIBIS II trials, the placebo mortality
rate and the mortality risk reduction of metoprolol
and bisoprolol are similar to that achieved by
carvedilol in COPERNICUS.22,23 For the CIBIS II
trial, NYHA class IV patients had an approximate
25% placebo mortality rate and a 26% reduction in
mortality based on 224 patients in the placebo group
and 221 patients in the treatment group.22 NYHA
class III patients had an approximate 16%–17% place-
bo mortality rate and a 34% reduction in mortality
based on 1096 patients in the placebo group and 1106
patients in the treatment group.22 In the MERIT-HF
subanalysis in NYHA class III and IV patients, the
placebo mortality rate was 19.1% and the risk reduc-
tion in total mortality was 39% in 396 placebo patients
and 399 treatment patients.23
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Table II. Outcomes of Mortality Trials
OUTCOMES* BEST CIBIS II CORPERNICUS MERIT-HF
Mortality reduction 10% (NS) 34% 35% 34%
Duration of study 2 Years 16 Months 10.4 Months 12 Months
Placebo mortality rate 33% 13.2% 18.5% 11%
Hospitalizations reduction 8% (NS) 20% N/A 18%
Withdrawal rates placebo vs. Tx 23% vs. 25% 15% vs. 15% 18.5% vs. 14.8% 15.3% vs. 13.9%
*As reported from each study; mortality reduction=total mortality risk reduction compared to placebo; hospitalization
reduction=total hospitalization risk reduction compared to placebo; withdrawal rates=permanent discontinuation of
treatment for each group; Tx=treatment group; NS=not statistically significant; trial acronyms expanded in the text
The only mortality trial not to show a benefit was
BEST.11 This trial is discussed in more detail in the
section on the impact of race. Bucindolol is a unique
agent and the patients in the BEST trial were differ-
ent in terms of the severity of the disease and racial
breakdown. It is unclear which of these factors is most
responsible for the outcome.
A direct comparison of the effect of two differ-
ent β blockers, carvedilol and metoprolol, on
mortality was performed in the COMET trial.21
In this trial, carvedilol reduced mortality by 17%
compared with metoprolol over a 58-month fol-
low-up period. However, the differences in the
dose and formulation of metoprolol between the
MERIT-HF and COMET trials may have con-
tributed to the apparent superiority of carvedilol.
In the MERIT-HF trial, patients received a high
dose of metoprolol (200 mg q.d. target/159 mg q.d.
achieved) in an extended-release formulation. In the
COMET trial, patients received a lower dose of meto-
prolol (50 mg b.i.d. target/85 mg q.d. achieved) in an
immediate-release formulation. Arguably, these differ-
ences in dose and formulation may not have produced
clinically significant differences in β blockade. Howev-
er, that contention is based on the lower bioavailability
of the extended-release formulation (approximately
65%) and on extrapolations from dose-response rela-
tionships in normal volunteers.24,25
Hospitalizations. Data for total hospitalizations are
shown in Table II.1,2,4,11,26 Once again, subgroup
analysis was done for patients with severe HF for the
CIBIS II and MERIT-HF trials.1,2 For CIBIS II, the
reduction in hospitalizations was 5% (95% confidence
interval [CI], 0.78–1.17) for NYHA class IV patients
and 17% (95% CI, 0.74–0.93) for class III patients.
For MERIT-HF, hospitalizations were reduced by
27% (p=0.0037). The data available for the COR-
PERNICUS trial show that 32.2% of the patients re-
ceiving carvedilol were hospitalized at least once vs.
38.1% for placebo (p=0.0029).27 Overall, all three of
these β blockers reduce hospitalizations and the re-
duction in hospitalizations appear to be similar
among the trials.
Tolerability. It has been discussed that since
carvedilol has vasodilating properties it should be
the best tolerated. To examine this, evaluating the
withdrawal rates among the trials is one approach.
As seen in Table II, the withdrawal rates were similar
in the treatment groups compared with placebo.
Metoprolol XL and carvedilol even demonstrated a
lower withdrawal rate than placebo. These data indi-
cate that all three β blockers evaluated are well toler-
ated in the treatment of HF compared with placebo.
Left Ventricular Ejection Fraction. There has been
no trial larger than 150 patients that has directly
compared the effects of a third generation β blocker
to a second generation β blocker.28 However, there
have been a number of smaller trials that have eval-
uated the impact of β blockers on improving ejec-
tion fraction either against placebo or active treat-
ment. In a meta-analysis,28 2184 patients from 19
randomized controlled trials of carvedilol or meto-
prolol were evaluated. The average duration of ther-
apy was approximately 8 months and the mean daily
dose of carvedilol was 58±1 mg and the equivalent
of 162±1 mg of metoprolol extended release. It is
stated that in 15 placebo-controlled trials, the place-
bo-corrected increase in ejection fraction for
carvedilol was 0.065 and 0.038 for metoprolol, both
of which were significantly increased compared with
their respective placebo controls (p<0.0001). From
these trials, the increase in ejection fraction for
carvedilol was significantly greater than with meto-
prolol (p=0.002; weighted mean of the treatment
differences was 0.026±0.007). In four trials in which
carvedilol and metoprolol were directly compared,
carvedilol increased ejection fraction by 0.084 with
metoprolol increasing ejection fraction by 0.057,
p=0.09. Overall, these data indicate that both
carvedilol and metoprolol significantly increase
ejection fraction compared with placebo and that
carvedilol may increase it to a greater extent. 
Practical Issues. Practical issues to consider are ease of
administration and cost. In this regard both bisoprolol
and metoprolol XL have slight advantages since both
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Table III. Cost Comparison
DRUG TARGET DOSE COST*
Bisoprolol (Zebeta) 10 mg q.d. $40.81
Carvedilol (Coreg) 25 mg b.i.d. $90.67
Metoprolol XL (Toprol XL) 200 mg q.d. $55.71
*Cost for a 30-day supply to consumers based on prices from drugstore.com, July 7, 2002
may be dosed once a day vs. twice a day for carvedilol.
In regard to cost, as seen in Table III, both bisoprolol
and metoprolol XL are lower than carvedilol for a 30-
day supply at target dose levels. This may have signifi-
cant implications in those patients who are not covered
with prescription insurance. Additionally, only
carvedilol and metoprolol succinate are approved by
the Food and Drug Administration (FDA) and dosed
appropriately for initiation in HF.
The most significant practical conclusion is that
β blockers (i.e., carvedilol, metoprolol XL, and
bisoprolol) significantly reduce mortality and hospi-
talizations in patients with HF and that all appro-
priate HF patients need to be considered for treat-
ment with any one of these β blockers.  
The Utility of β Blockers Among
Patients With NYHA Class I and
NYHA Class IV Symptoms
NYHA Class I. None of the major clinical trials
which have established the efficacy of bisoprolol,
carvedilol, and metoprolol in HF have systematically
enrolled NYHA class I patients.1–4 The Carvedilol
Post-Infarction Survival Control in Left Ventricular
Dysfunction (CAPRICORN) study did enroll some
asymptomatic patients and detected a trend toward
improved mortality.29 It is hard to generalize these
findings to all NYHA class I patients because all of
the patients were postmyocardial infarction, no sub-
group analysis was published isolating class I pa-
tients, and there were some statistical concerns.
The epidemiology of this class is poorly character-
ized, but some data are emerging. McDonagh30 re-
viewed the available epidemiologic literature and de-
scribed studies with different methodologies on differ-
ent populations revealing a prevalence range from
1.4%–6.8%. In the North Glascow MONICA (monitor-
ing cardiovascular disease) population study,31 71% of
these asymptomatic patients had evidence of ischemic
heart disease. Hypertension was predictive in the
presence of heart disease but was not an independent
predictor.30 The prevention arm of the Studies of Left
Ventricular Dysfunction (SOLVD) also looked at
asymptomatic patients, but recruitment was aimed at
patients with known heart disease so this register may
not be representative of the general population.32
The outcome of patients with asymptomatic HF
is poor. The Framingham study33 revealed that
men with a decrease in fractional shortening of 4%
had a relative risk of a cardiovascular event of 1.42
(95% CI, 1.12–1.81) within 4 years. In SOLVD,31
placebo mortality was 15.8% at an average follow-
up of 37.4 months.
In spite of the above data, there are no recommen-
dations to perform routine screening of the general
population or even of high-risk patients for asympto-
matic HF. It is reasonable to assume that a large per-
centage of NYHA I patients will be identified as part
of an evaluation for hypertension or heart disease. In
both of these instances, β blockers are indicated. We
are unaware of any ongoing trials with β blockers in
NYHA class I patients. Data will not be forthcoming
soon to clarify this issue. The only evidence to sup-
port treating asymptomatic patients with β blockers
comes from the expectation that many of the asymp-
tomatic patients identified will have comorbid condi-
tions justifying their use.
NYHA Class IV. Two trials have been published that
sought to evaluate the efficacy of β blockers among
patients with advanced, chronic HF—COPERNICUS
and BEST.4,11 The other β blocker mortality trials
had insufficient numbers of class IV patients.
COPERNICUS enrolled 2289 patients chosen be-
cause they had symptoms at rest or with minimal exer-
tion for at least 2 months and an ejection fraction of
less than 25%. All were on some combination of thera-
py that included ACE inhibitors, diuretics, digitalis,
and spironolactone. Among those excluded were pa-
tients needing intravenous inotropes or vasodilators,
those with marked congestive symptoms, and those re-
quiring intensive care for their HF symptoms.
The COPERNICUS study was terminated early (av-
erage duration of therapy, 10.4 months) by the data
safety monitoring board because of the significance of
the beneficial impact of carvedilol on mortality. The
risk of death at 1 year was 18.5% in the placebo group
and 11.4% in the treatment group. This 35% relative
reduction in the risk of death was extended to the sub-
group of patients with the lowest ejection fraction.
Though the magnitude of the benefit is impressive,
the findings do not necessarily justify the use of
carvedilol among the sickest HF patients. Significantly
decompensated patients were excluded from this trial
and the placebo mortality rate was lower than might
be expected for a study of class IV patients. Therefore,
this trial does not justify the use of carvedilol in pa-
tients who are hypotensive, significantly volume over-
loaded, requiring intravenous inotropic agents, or re-
quiring care in an intensive care unit.
The BEST trial11 is discussed in more detail in the
section on racial differences in response to medica-
tion. Though the trial was designed to study the effica-
cy of bucindolol among patients with advanced HF,
there are several factors limiting the applicability of
this trial. Only 8% of the enrolled patients were
NYHA class IV and the authors concede that conclu-
sions cannot be made about the effect of bucindolol in
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these patients. The overall trial was neutral with re-
gard to the mortality impact of bucindolol. Bucindolol
cannot be recommended in class IV patients.
Patients presenting with symptoms of decompensat-
ed HF may do so either on or off β blockers. A prudent
approach for patients who have been previously com-
pensated while on a stable dose of a β blocker would be
to continue the β blockers unless the patient is hemody-
namically unstable. In that setting, the β blocker should
be discontinued but may be reconsidered when the pa-
tient is stable again. Among patients presenting with
class IV symptoms and not on a β blocker, diuretics and
ACE inhibitors should be started first. The initiation of
β blockers can await the patient’s stabilization. 
The Impact of Race on the 
Efficacy of β Blockers
Racial differences in the epidemiology and mortali-
ty risk of HF have been described.10,34,35 Analysis of
hospitalization records reveals a pattern of black
patients with HF being younger, having more hy-
pertension, more diabetes, more renal disease, less
ischemic disease, and higher readmission rates than
white patients.10,34
Mortality patterns are less consistent. National
mortality data in 1995 reveal an age-adjusted death
rate due to HF among people older than 65 years as
1.08-times as high for black men as for white men
and 1.06 times as high for black women as for white
women.36 In contrast, Alexander and colleagues10
found a lower postdischarge mortality rate among
blacks at 1 year and Philbin and DiSalvo34 found a
relative inhospital mortality rate for blacks of 0.832.
If mortality differences exist between races it is un-
clear if they are due to differences in comorbidities,
access to care, or other factors. 
Recently, the focus has been on understanding a
possible differential racial response to medications.
Recent retrospective analyses of data gathered in
the Vasodilator Heart Failure Trials (V-HeFT I and
V-HeFT II)37 and in SOLVD38 illustrate this point.
In V-HeFT I,37 there was a significant decrease in
mortality among black patients, but not white pa-
tients, who received hydralazine plus isosorbide
dinitrate (H-I). The placebo mortality rate was simi-
lar between the races. In V-HeFT II,37 treatment
with enalapril vs. H-I demonstrated a mortality
benefit only among white patients. Finally, a
matched cohort analysis of data from SOLVD38 re-
vealed that enalapril was associated with a signifi-
cant reduction in hospitalizations (44%; 95% CI,
27–57), systolic blood pressure (5.0±17.1 mm Hg),
and diastolic blood pressure (3.6±10.6 mm Hg)
among white patients but not among black patients.
In the placebo group, the black patients had a high-
er mortality rate than that of the white matched
controls. There was no statistically significant mor-
tality benefit of enalapril in either group.
Racial differences may exist in β blocker responsive-
ness as well. Rutledge39 compiled data from studies
looking at racial responsiveness to β blockade and found
that normotensive blacks and whites respond differently
to β blockade, that hypertensive blacks are relatively hy-
poresponsive with whites when β blockers are given as
monotherapy, and that β blockers with alpha properties
may be equally efficacious among blacks and whites.
The BEST trial is the only β blocker mortality
trial designed prospectively to examine the impact
of race on the effectiveness of β blockers in HF.19
Interpretation of this study is difficult. Overall, the
trial was neutral, with annualized mortality rates in
the placebo and treatment groups of 33% and 30%,
respectively (p=0.13). However, the trial was termi-
nated early because of the “totality of evidence re-
garding the usefulness of β blocker treatment de-
rived from BEST and other studies.” The BEST
study revealed a significant improvement in mortal-
ity among nonblack patients (hazard ratio, 0.82;
95% CI, 0.70–0.96) but a trend toward harm among
black patients (hazard ratio, 1.17; 95% CI,
0.89–1.53). Bucindolol has never been proved to
have a mortality benefit in HF patients in any large
randomized trial, so it is difficult to know which of
the results from BEST are idiosyncratic and which
are generalizable.
Twenty-three percent of the patients enrolled in
BEST were black, CIBIS II and COPERNICUS did
not report a racial breakdown, and MERIT-HF en-
rolled less than 5% blacks.1,2,4 The investigators in the
US Carvedilol Heart Failure Trials37 conducted a post
hoc analysis of the impact of carvedilol among black
patients. They revealed a statistically significant im-
provement in mortality among nonblack patients (rel-
ative risk, 0.32; 95% CI, 0.17–0.62) but an insignifi-
cant difference among black patients (relative risk
0.44; 95% CI, 0.15–1.28). Composite end points of
death plus hospitalization showed benefit among both
groups. The limitations of this study have been de-
scribed elsewhere in this paper.
It is difficult to form conclusions regarding these
trends indicating racial differences. Race is difficult
to define and is clearly not a pure distinction. Dif-
ferences in epidemiology have been described
based upon the geographic origin of the black pop-
ulation.41 Racial differences may reflect the
frequency of polymorphisms rather than their pres-
ence or absence in one group vs. another. There are
insufficient data at this time to withhold β blockers
based upon race.
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Interactions With Other 
Medications Commonly Used
in the Treatment of HF
ACE Inhibitors and Diuretics. Beta blockers clearly
improve survival among patients with HF who are
already receiving ACE inhibitors and diuretics. In
the three pivotal β blocker trials—CIBIS II,
MERIT-HF, and COPERNICUS—the vast majority
of patients were taking an ACE inhibitor
(89%–96%) and a diuretic (90%–99%) as part of
background therapy.1,2,4 Ironically, the beneficial
effects of β blockers in the absence of these drugs
has not been established in large mortality trials
and must be inferred.
Aldosterone Antagonists. Beta blockers also appear
to improve survival among patients with HF who
are receiving spironolactone in addition to ACE in-
hibitors and diuretics. However, the number of pa-
tients supporting this conclusion is small. In
COPERNICUS,4 20% of the patients were taking
spironolactone without reported adverse effects
during the addition of carvedilol. In RALES,12 10%
of the patients were taking β blockers in addition to
ACE inhibitors and diuretics. In this subgroup,
spironolactone appeared to produce greater benefit
than in patients who were not receiving β blockers.
Another aldersterone antagonist, eplerenone, was
tested in postinfarction patients with HF in the
Eplerenone Post-Acute Myocardial Infarction Heart
Failure Efficacy and Survival Study (EPHESUS).42
In EPHESUS, 75% of patients were on β blockers.
Overall mortality was reduced from 16.7% to 14.4%
over 16 months with the addition of eplerenone. A sub-
group analysis of patients on both angiotensin block-
ade and β blockade revealed a reduction in mortality of
approximately 25%, which is greater than that of the
overall trial. These data imply that adding aldersterone
blockade to β blockade is beneficial.
Angiotensin Receptor Blockers. ARBs appear to
increase mortality among patients with HF who are
also receiving β blockers and ACE inhibitors. In
Val-HeFT,11 the largest mortality trial of an ARB in
HF reported to date, valsartan increased the risk of
mortality by more than 40% compared with placebo
in patients receiving β blockers and ACE inhibitors.
Whether ARBs interact negatively with β blockers,
ACE inhibitors, or only the combination of the two,
remains uncertain. In the 140 patient subgroup in
Val-HeFT receiving only a β blocker without an
ACE inhibitor, valsartan had a statistically uncer-
tain effect on mortality.
The Evaluation of Losartan in the Elderly
(ELITE-II) study43 also suggested a potential nega-
tive interaction between β blockers and ARBs in pa-
tients with HF. Although there was no placebo arm
in ELITE II, therapy with the ARB losartan in-
creased mortality compared to therapy with the
ACE inhibitor captopril among the 20% of patients
who were receiving β blockers.
Despite these data, at least one other trial of ARBs
in HF patients who may also be receiving β blockers
has not reported a negative interaction. In the Ran-
domized Evaluation of Strategies for Left Ventricular
Dysfunction (RESOLVD) pilot study, patients initially
randomized to an ACE inhibitor, ARB, or combination
of ACE inhibitor and ARB, were later further random-
ized to metoprolol or placebo without reported nega-
tive interaction between β blocker and ARB therapy.44
Additional data may also be available describing the
impact of candesartan and β blockers when results
from the Candesartan in Heart Failure—Assessment of
Reduction in Mortality and Morbidity (CHARM) study
are released. Therefore, conclusions about a negative
impact of β blockers in patients also receiving ARBs
should be tentative and subject to review of additional
data when they are available. 
Beta blockers should be administered in combi-
nation with ACE inhibitors and diuretics to patients
with HF. Pending the results of the EPHESUS trial,
β blockers can also be administered to patients re-
ceiving aldosterone antagonists. The currently
available data do not support the addition of ARB
therapy to patients with HF who are receiving ACE
inhibitors and β blockers. 
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